Why Your CJC+Ipamorelin Isn't Working on Retatrutide

The standard rule for growth hormone peptides has always been simple: wait two hours after eating, then inject. Two hours is long enough for your stomach to empty, your insulin to drop, and your pituitary to respond cleanly to whatever secretagogue you are using. That rule works well enough for most people.

But most people are not on retatrutide.

To understand why that matters, you need the full picture first. When you eat, your blood glucose rises and your pancreas releases insulin to manage it. That insulin does not just work on your muscles and fat cells. It also acts on your pituitary gland, specifically on the cells there that release growth hormone, and it suppresses them. So if insulin is elevated and you inject CJC+Ipamorelin, you are sending a signal to release growth hormone at the same moment that a different signal is telling the pituitary to hold back. The two signals work against each other, and the suppressive one tends to win.

This is the entire reason fasted dosing exists. You wait until food is absorbed, insulin falls back to baseline, and only then does your growth hormone pulse actually have room to happen. The two hour window is based on how long it normally takes a typical mixed meal to clear your stomach far enough that the insulin spike is winding down.

The problem is that retatrutide does not let your stomach work normally.

Retatrutide acts on three receptors: GIP, GLP-1, and glucagon. The GLP-1 component is what is relevant here, because GLP-1 receptor activation slows something called gastric emptying, which is just the rate at which food moves out of your stomach and into your small intestine. Slower gastric emptying means food sits in your stomach longer, glucose enters your bloodstream more gradually, and the insulin response is stretched out over a longer window instead of rising and falling cleanly.

Researchers measured exactly how much GLP-1 drugs change this. In one study on semaglutide, gastric half-emptying time, which is the point at which half of a meal has left the stomach, increased from 118 minutes to 171 minutes. That is almost an hour of extra delay. And at the two hour mark specifically, participants on the drug had roughly 25 percent more food still retained in their stomach compared to people not on the drug. At three hours, that gap widened to 38 percent more retained. The delay does not resolve as you move further from the meal. It compounds.

Retatrutide data shows the same pattern. Doses at 3mg and above delayed the absorption peak of a test substance by approximately one hour, with those effects still measurable at day 30 and day 79 of treatment. This is not an acute effect that your body adapts to quickly. It persists.

The anesthesiology field noticed this before most people in the performance space did. Anesthesiologists need to know whether a patient's stomach is truly empty before surgery because a full stomach creates aspiration risk under sedation. The standard pre-surgical fast had always been enough of a buffer. Then GLP-1 drugs became widespread and studies started showing that patients who had fasted for seven to eighteen hours still had retained solid gastric contents. The professional guidelines changed because the old fasting window could no longer be trusted on these drugs.

Now apply that to your two hour post-meal injection window. You eat dinner at seven. You inject at nine, confident you have waited long enough. But based on the gastric emptying data, you are likely still absorbing that meal. Glucose is still entering your bloodstream. Insulin is still elevated. And that insulin is sitting on your pituitary right at the moment you are trying to generate a growth hormone pulse. You are running two opposing systems simultaneously, and you have been doing it thinking you were following the rules.

The fix is straightforward. Move your growth hormone peptides to the morning, first thing after waking.

After eight to ten hours of overnight fasting, your stomach is empty regardless of how slowly retatrutide is processing things. Whatever you ate for dinner has had the full night to clear. Your insulin is at its lowest point of the day. There is no competing signal. The pituitary is ready to respond.

The one thing worth knowing about morning timing is that you want to eat within thirty to sixty minutes after injecting. This is not about comfort. Growth hormone itself does not do much until your liver converts it into something called IGF-1, which is insulin-like growth factor 1, the downstream molecule responsible for most of the tissue effects people are actually after. That conversion requires insulin to be present in the liver. So you need some food and the insulin response that follows to complete the process. The morning window gives you a clean pulse first, then the metabolic infrastructure to use it.

A 1990 study comparing morning versus evening growth hormone injections in GH-deficient patients found that 24-hour IGF-1 levels were equivalent between the two timing approaches. Morning dosing is not a workaround or a compromise. It produces the same output. It is just the window that operates independently of what retatrutide is doing to your digestion.

The deeper point here is that stacking compounds does not just add their effects together. It changes the environment each one is operating in. Retatrutide's gastric slowing is not a side effect you experience and move on from. It is a persistent physiological state that alters the timing assumptions every other compound in your protocol was built around.

Two hours is the right rule for a normal stomach. On a GLP-1 drug, there is no such thing as a normal stomach anymore.

---

References

1. Urva S, Coskun T, Loghin C, et al. 2023. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes, Obesity and Metabolism. Finding: Retatrutide at doses ≥3mg delayed acetaminophen Tmax by approximately 1 hour, with effects persisting at Day 30 and Day 79. Source
2. Jensterle M, et al. 2023. Semaglutide delays 4-hour gastric emptying in women with polycystic ovary syndrome and obesity. Diabetes, Obesity and Metabolism. Finding: Gastric half-emptying time increased from 118 minutes to 171 minutes on semaglutide. At 2 hours, 25.5% more gastric contents retained vs placebo. At 3 hours, 38% more retained. Source
3. Silveira SQ, et al. 2023. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. Journal of Clinical Endocrinology \& Metabolism. Finding: GLP-1 RA patients had gastric half-emptying of 138 minutes vs 95 minutes on placebo. Patients fasting 7-18 hours still had retained solid gastric contents. Source
4. Jorgensen JO, et al. 1990. Evening versus morning injections of growth hormone in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. Finding: 24-hour IGF-1 levels were equivalent between morning and evening injection timing. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness